BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

  October 20, 2025

   · 

  8 min read
• Press Releases

  Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

  October 20, 2025

   · 

  2 min read
• Press Releases

  Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress

  October 20, 2025

   · 

  4 min read
• Press Releases

  Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

  October 20, 2025

   · 

  19 min read
• Press Releases

  ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

  October 20, 2025

   · 

  6 min read
• Press Releases

  General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025

  October 20, 2025

   · 

  5 min read
• Press Releases

  Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

  October 20, 2025

   · 

  13 min read
• Press Releases

  TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

  October 20, 2025

   · 

  14 min read
• Press Releases

  Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

  October 20, 2025

   · 

  13 min read
• Press Releases

  Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

  October 20, 2025

   · 

  8 min read